Treatment-related esophagitis

Seminars in Oncology

Volumn 32, Issue SUPPL. 3, 2005, Pages 60-66

  Werner Wasik, Maria ^a,b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; RADIOPROTECTIVE AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS; FEEDING APPARATUS; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PROTECTION; RADIOSENSITIZATION; SPINAL CORD; TOXICITY; LUNG TUMOR; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOTHERAPY; REVIEW;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; DOSE FRACTIONATION; ESOPHAGITIS; HUMANS; LUNG NEOPLASMS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY;

EID: 18144421195     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.03.011     Document Type: Conference Paper

References (32)

1. D.R. Gandara, K. Chansky, K.S. Albain Southwest Oncology Group Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer Phase II Southwest Oncology Group Study S9504 J Clin Oncol 15 2003 2004 2010
2. W. Curran Jr, C. Scott, C. Langer Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer Initial report of RTOG 9410 Proc Am Soc Clin Oncol 19 2000 484a (abstr 1891)
3. K. Furuse, M. Fukuoka, M. Kawahara Phase III study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer J Clin Oncol 17 1999 2692 2699
4. M. Werner-Wasik, E. Pequignot, D. Leeper Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus A multivariate analysis of patients with lung cancer treated with non-operative therapy Int J Radiat Oncol Biol Phys 48 2000 689 696
5. R.W. Byhardt, C. Scott, W.T. Sause Response, toxicity, failure patterns, and survival in five RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung Int J Radiat Oncol Biol Phys 42 1998 469 478
6. M. Werner-Wasik, C. Scott, M.L. Graham Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy A multivariate analysis of 1076 RTOG patients Int J Radiat Oncol Biol Phys 44 1999 327 331
7. M. Werner-Wasik, R.S. Axelrod, D.P. Friedland Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy Clin Lung Cancer 2 2001 284 289
8. E.E. Vokes, K.A. Leopold, J.E. Herndon A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431) Proc Am Soc Clin Oncol 18 1999 459a (abstr 1771)
9. M. Werner-Wasik, C. Scott, J.D. Cox Correlation between acute esophagitis and late pneumonitis in patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent thoracic radiotherapy (RT) and chemotherapy A multivariate analysis of the Radiation Therapy Oncology Group (RTOG) database Proc Am Soc Clin Oncol 21 2002 299a (abstr 1192)
10. J.D. Cox, T.F. Pajak, S. Asbell Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung Analysis of 1244 cases from 3 RTOG trials Int J Radiat Oncol Biol Phys 27 1993 493 498
11. S. Hirota, K. Tsujino, Y. Hishikawa Endoscopic findings of radiation esophagitis in concurrent chemoradiotherapy for intrathoracic malignancies Radiother Oncol 58 2001 273 278
12. M. Werner-Wasik, S.A. Axelrod, D.P. Friedland Phase II trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemotherapy Semin Radiat Oncol 12 suppl 1 2002 34 39
13. B. Movsas, C. Scott, C. Langer Phase III study of amifostine in patients with locally advanced non-small cell lung cancer receiving intensive chemoradiation Radiation Therapy Oncology Group 98-01 Proc Am Soc Clin Oncol 22 2003 636 (abstr 2459)
14. D. Ball, J. Bishop, J. Smith A phase III study of accelerated radiotherapy with and without carboplatin in non-small cell lung cancer An interim toxicity analysis of the first 100 patients Int J Radiat Oncol Biol Phys 31 1995 267 272
15. M.I. Saunders, S. Dische, A. Barrett Randomized multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer An interim report Br J Cancer 73 1996 1455 1462
16. A. Michalowski, S. Hornsey Assays of damage to the alimentary canal Br J Cancer 53 suppl VII 1986 1 6
17. H. Choy, K. LaPorte, E. Knill-Selby Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer Semin Radiat Oncol 9 1999 90 96
18. C.J. Langer Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer Semin Radiat Oncol 9 1999 108 116
19. B. Emami, J. Lyman, A. Brown Tolerance of normal tissue to therapeutic irradiation Int J Radiat Oncol Biol Phys 21 1991 109 122
20. Maguire, G.S. Sibley, S.M. Zhou Clinical and dosimetric predictors of radiation-induced esophageal toxicity Int J Radiat Oncol Biol Phys 45 1999 97 103
21. A.K. Singh, M.A. Lockett, J.D. Bradley Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiotherapy Int J Radiat Oncol Biol Phys 55 2003 337 341
22. J. Bradley, J.O. Deasy, S. Bentzen Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma Int J Radiat Oncol Biol Phys 58 2004 1106 1113
23. G. Fletcher Clinical dose-response curves of human malignant epithelial tumors Br J Radiol 46 1973 1 12
24. J.A. Hayman, M.K. Martel, R.K. Ten Haken Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy Update of a phase I trial J Clin Oncol 19 2001 127 136
25. M.V. Graham, J.W. Matthews, W.B. Harms Three-dimensional radiation treatment planning study for patients with carcinoma of the lung Int J Radiat Oncol Biol Phys 29 1994 1105 1117
26. Y. Xiao, M. Werner-Wasik, D. Michalski Comparison of three IMRT inverse planning techniques that allow for partial esophagus sparing in patients receiving thoracic radiation therapy for lung cancer Med Dosim 29 2004 210 216
27. B. Emami, N. Mirkovic, C. Scott The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer An analysisal of RTOG data Lung Cancer 41 2003 207 214
28. H. Ito, M.L. Meistrich, Ht Barkley Jr Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721 Int J Radiat Oncol Biol Phys 12 1986 211 219
29. D. Antonadou, N. Coliarakis, M. Synodinou Randomized phase III trial of radiation treatment plus/minus amifostine in patients with advanced-stage lung cancer Int J Radiat Oncol Biol Phys 51 2001 915 922
30. D. Antonadou Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer Semin Radiat Oncol 12 suppl 1 2002 50 58
31. R. Komaki, J.S. Lee, B. Kaplan Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage I-III non-small cell lung cancer Preliminary results Semin Radiat Oncol 12 suppl 1 2002 46 49
32. S.S. Leong, E.H. Tan, K.W. Fong Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small cell lung cancer J Clin Oncol 21 2003 1767 1774